By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BeiGene Co.,Ltd 

No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
Changping District  Beijing    China
Phone: n/a Fax: n/a



Company News
BeiGene Co.,Ltd Announces IND Approval For BGB-3111, A Bruton Tyrosine Kinase Inhibitor 6/19/2015 10:48:36 AM
BeiGene Co.,Ltd Enrolls First Patient In Phase I Study Of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody 6/8/2015 7:25:47 AM
Week In Review: BeiGene Co.,Ltd Raises $97 Million For Cancer Drugs 5/18/2015 8:45:16 AM
BeiGene Co.,Ltd Nabs $97 Million 5/13/2015 7:30:09 AM
China's BeiGene Co.,Ltd Selects SAFC CHOZN Platform for Commercial Drug Development 3/11/2015 7:02:00 AM
BeiGene Co.,Ltd Bags $75 Million 11/14/2014 10:49:25 AM
BeiGene Co.,Ltd Receives Clinical Milestone Payment For Development Of BGB-290 9/15/2014 8:14:20 AM
BeiGene Co.,Ltd Signs China CMO Deal With Boehringer Ingelheim Corporation 9/4/2014 2:41:40 PM
BeiGene Co.,Ltd Expands Management Team With Two Strategic Senior Positions 8/27/2014 9:08:28 AM
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111 8/26/2014 10:32:17 AM